NewsDialy
Junshi Biosciences has entered a licensing collaboration with Fosun Wanbang to develop and commercialize roconkibart across the Greater China Region.
Roconkibart targets interleukin-17A, a cytokine tied to inflammatory disease.
The agreement positions Fosun Wanbang as Junshi's regional partner on the asset in one of the world's most consequential pharmaceutical markets.
What Roconkibart's Target, IL-17A, Actually Does Interleukin-17A is a signaling protein the immune system uses to orchestrate inflammatory responses. Under normal conditions, it helps defend against pathogens.
Keep reading